1,000,000 + Attorneys and Legal Staff - Legal employers hire more people on LawCrossing than any other site.
Halliburton Settles Oil Spill Claims at $1.1 Billion
Halliburton Settles Oil Spill Claims at $1.1 Billion
Google Announces Drone Delivery Service: Project Wing to Be Available in “Less than a Decade”
Google Announces Drone Delivery Service: Project Wing to Be Available ...
Livedrive Riles UK Customers by Abruptly Terminating Services
Livedrive Riles UK Customers by Abruptly Terminating Services
Jury Verdict Against Bank of America to be Reviewed by Judge
Jury Verdict Against Bank of America to be Reviewed by Judge
Job Listings

Teva Pharmaceutical Industries Tries to Block Generic Competition

Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company that specializes in the development, production and marketing of generic and proprietary branded pharmaceuticals and active pharmaceutical ingredients. Teva Pharmaceuticals is among the top 20 pharmaceutical companies and among the largest generic pharmaceutical companies in the world.

Several companies have made notable advancements this year in treating multiple sclerosis, a debilitating disease in which the body’s immune system attacks the central nervous system. MS affects an estimated 2.5 million people worldwide and 400,000 people in the United States. There is no cure for MS, and treatments have often caused terrible side effects, such as birth defects, cancer, and the risk of rare brain infections.

Biogen, Sanofi, and Novartis are the most promising advancements in the MS treatment market. Gains made by Biogen, Sanofi, and Novartis could sink Teva in 2014. Mylan and Momenta Pharmaceuticals, which is partnered with Novartis subsidiary Sandoz, have already declared their intentions to launch generic Copaxone when Teva’s patent expires. Teva doesn’t have much time left to switch patients over to its new, thrice-weekly Copaxone injection before generics jump on the current product.

What

 job title, keywords

Where

 city, state, zip



Get JD Journal in Your Mail
Subscribe to our FREE daily news alerts and get the latest updates on the most happening events in the legal, business, and celebrity world. You also get your daily dose of humor and entertainment!!


The injectable treatment, Copaxone, Teva Pharmaceutical Industries multiple sclerosis drug’s patent is about to run out and according to Bloomberg News, The U.S. Supreme Court took no action on the four Teva patents that expire in May that would have blocked generic competition until September 2015.

Last quarter according to Bloomberg News, the injectable MS drug Copaxone, generated $1.05 billion in revenue for Teva, which accounted for 21% of the company’s top line. However, sales of Copaxone are set to plunge next year, due to rising competition from the newer oral drugs and the expiration of the key patent which expires in May 2014.

Finding new sources of revenue to offset an expected drop in Copaxone sales will be one of the challenges for Erez Vigodman, who took over as Teva’s chief executive officer, according to Bloomberg News. His predecessor, Jeremy Levin, left after a dispute with the board over how to overhaul Teva.

Image credit: www.businessweek.com

Teva Pharmaceutical Industries Tries to Block Generic Competition by

Tagged:

Jaan Posted by on March 13, 2014. Filed under Business News,Home. You can follow any responses to this entry through the RSS 2.0. You can skip to the end and leave a response. Pinging is currently not allowed.

 

 

Job of the Day
LAW FIRM BOOKKEEPER
USA-FL-Coral Gables

Well established South Miami law firm seeks full charge bookkeeper with Perfectlaw experience. Must have full knowledge of bookkeeping through financial statements. Extensive reporting required and ad...